Latest Content

A new study reveals global gaps in integrative oncology knowledge, highlighting communication and the role of APPs in community settings.

New Phase 3 ENDURANCE trial data shows no survival benefit for indefinite lenalidomide maintenance over 2 years in non-transplant myeloma patients.

FDA approves Tudriqev with nivolumab for advanced cutaneous melanoma. Learn about dosing, safety warnings, and trial data for oncology nurses.

Explore how brain cancer-related fatigue impacts patient identity and learn practical person-centered care strategies for nurses and doctors.

Theresa Lynne Harrington Stukus, ANPBC NP, discusses managing the influx of new breast cancer therapies and the importance of professional networking.

New research shows high-dose oral vitamin D provides rapid relief for chemo-induced erythema and radiation dermatitis without toxicity.

Oncology nurses must differentiate cyclospora from treatment side effects and use PCR-based GI panels to ensure rapid diagnosis during the outbreak.

Oncology nurse Pattie Jakel shares her story of ILC recurrence, highlighting why MRI and specialized education are vital for lobular breast cancer.

A study of 400,000 Medicare beneficiaries finds that while genomic testing is rising, next-generation sequencing remains underutilized in cancer care.

Michelle Mollica, PhD, RN, discusses training oncology nurses to manage information overload and guide patients post-diagnosis.

FDA approves Pluvicto with ARPI for PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer based on rPFS data.

Handa Oncology received FDA tentative approval for Omcazio capsules, a novel cabozantinib formulation with improved absorption and no food effects.

Learn how supportive culture and connection can improve oncology nurse retention and address burnout, shifting focus from individual responsibility.